Ukoniq Launch Starts TG Therapeutics' Commercial Path
Executive Summary
A first-in-class PI3K/CK1 epsilon inhibitor, Ukoniq was approved by the US FDA for two types of lymphoma.
You may also be interested in...
Ukoniq Lifts Alembic-Backed Rhizen, India Debut On Cards
Rhizen is entitled to royalties on net sales of US FDA-approved Ukoniq, being commercialized by partner TG Therapeutics, and expects to take the lymphoma treatment to India. CEO suggests the first-in-class PI3K/CK1 epsilon inhibitor, discovered by Rhizen, bests competitors including Bayer's Aliqopa.
TG Therapeutics Looks To Market Ublituximab On Convenience, Pricing In MS
The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.
TG Therapeutics Raises $60m Following Combo Therapy Success In CLL
One day after reporting that its umbralisib/ublituximab combo met a PFS endpoint in CLL, TG raises $60m as it prepares for a year-end filing of the combo. Umbralisib monotherapy is under FDA review already.
Need a specific report? 1000+ reports available
Buy Reports